



Medicines & Healthcare products
Regulatory Agency

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom
[gov.uk/mhra](https://www.gov.uk/mhra)

[REDACTED]

25 August 2023

FOI 23/563

Dear [REDACTED]

Thank you for your information request, dated 1st August 2023, where you asked for the number of adverse reaction reports related to e-cigarettes received for the financial years 2021/22 and 2022/23 and a breakdown of the adverse reactions reported for the financial year 2022/23.

I can confirm that in the financial year 2021/22, 6th April 2021 to 5th April 2022, the MHRA received 28 suspected adverse reaction (ADR) reports associated with nicotine-containing e-cigarettes through the Yellow Card scheme. In the following financial year, 6th April 2022 to 5th April 2023, the MHRA received 47 suspected ADR reports associated with nicotine-containing e-cigarettes.

The attached e-cigarette Drug Analysis Print (DAP) provides a breakdown of the 47 suspected ADR reports received between 6th April 2022 and 5th April 2023.

When considering this data, it is important to be aware that reporters are asked to submit Yellow Card reports even if they only have a suspicion that an e-cigarette may have caused an ADR. Many factors including underlying or previously undiagnosed illness unrelated to an e-cigarette have to be considered when assessing whether an e-cigarette has caused an ADR. Further details on interpreting the DAP can be found in the accompanying E-Cigarette Analysis Print interpretation guide.

A summary of all suspected adverse reactions associated with nicotine-containing e-cigarettes reported through the Yellow Card scheme can also be viewed on our [e-cigarette Analysis Print](#). Please refer to the [accompanying guidance document](#) for information on how this data should be interpreted.



Medicines & Healthcare products Regulatory Agency

I hope the information provided is helpful. If you have a query about the information provided, please reply to this email.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: info@mhra.gov.uk.

Please remember to quote the reference number above in any future communications.

Yours sincerely,

Safety and Surveillance group
Medicines and Healthcare products Regulatory Agency

The MHRA information supplied in response to your request is subject to Crown copyright. The FOIA only entitles you to access to MHRA information.

For information on the reproduction or re-use of MHRA information, please visit <https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information>

If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, 4-T, Medicines and Healthcare products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Copyright notice

The information supplied in response to your request is the copyright of MHRA and/or a third party or parties and has been supplied for your personal use only. You may not sell, resell or otherwise use any information provided without prior agreement from the copyright holder.